Summary of Study ST001719
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001053. The data can be accessed directly via it's Project DOI: 10.21228/M8KQ59 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001719 |
| Study Title | Metabolomics Analysis of Philadelphia Cohort - Update (part-I) |
| Study Type | Metabolomics Analysis |
| Study Summary | Global metabolomics analysis of Philadelphia cohort |
| Institute | The Wistar Institute |
| Last Name | Abdel-Mohsen |
| First Name | Mohamed |
| Address | 3601 Spruce St, Philadelphia, PA 19104 |
| mmohsen@wistar.org | |
| Phone | 215-898-6008 |
| Submit Date | 2021-01-07 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2021-05-25 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO001789 |
| Collection Summary: | Analyses were performed from banked plasma samples of two different cohorts that underwent analytical treatment interruption (ATI): (1) Philadelphia Cohort and (2) ACTG cohort. In the Philadelphia cohort, HIV+ individuals on suppressive ART underwent an open-ended ATI without concurrent immunomodulatory agents. The ACTG cohort combined 74 HIV-infected ART-suppressed participants who underwent ATI from six ACTG ATI studies (ACTG 371,28 A5024,29 A5068,30 A5170,31 A5187,32 and A519733). 27 of these 74 individuals exhibited a PTC phenotype post-ATI, i.e. these individuals remained off ART for ≥24 weeks post-treatment interruption, sustained virologic control for at least 24 weeks, maintained viral load (VL) ≤400 copies for at least 2/3 of time points, had plasma drug level testing performed, and had no evidence of spontaneous control pre-ART. The remaining 47 cohort members were non-controllers (NCs) who exhibited virologic rebound before meeting PTC criteria. These two groups were matched for gender, age, % treated at the early stage of HIV infection, ART duration, pre-ATI CD4 count, and ethnicity. All analyses were performed on samples collected immediately before ATI in both cohorts. |
| Sample Type: | Blood (plasma) |
